ognizes an epitope of CD44 that is
highly expressed in liver cancers. Abstract 662, Section 27, Board
15, Sunday, Apr 15, 8AM - 12PM
ARH460-16-2, a functional antibody that targets CD44, has
previously been shown to have anti-tumor and survival benefits in
animal models of breast and prostate cancers. New
immunohistochemistry (IHC) studies demonstrated high levels of
ARH460-16-2 binding to primary liver tumors: 43% (21/49). The
antibody also bound more frequently to metastatic than to primary
hepatocellular carcinomas, 88% (7/8) versus 30% (11/37), and there
was a trend towards higher binding in advanced AJCC stages in
comparison with earlier stages: 0% (stage I), 12% (stage II), 50%
(stage III) and 75% (stage IV). In vivo studies are currently under
way, to assess the therapeutic effect of this antibody in an in
vivo model of metastatic hepatocellular carcinoma.
Functional antibodies targeting Trop-2 demonstrate in vivo efficacy
in human pancreatic and other solid tumor xenograft models.
Abstract 904, Section 5, Board 3, Sunday, Apr
15, 1PM - 5PM
Two monoclonal antibodies directed against Trop-2, AR47A6.4.2 and
AR52A301.5, have been independently generated which, in in vitro
assays, induce cytotoxicity in pancreatic, colon, lung and ovarian
cancer cell lines.
Experiments conducted using the human pancreatic BxPC-3 xenograft
model demonstrated that treatment with these antibodies resulted in
tumor growth inhibition in both prophylactic and established
models. The in vivo anti-tumor efficacy of these antibodies was
examined in models of other solid tumor cancer indications, and the
anti-tumor effect in human pancreatic cancer was substantiated by a
second model of human pancreatic cancer. With the aim of bringing
these antibodies to the clinic, the selection of an animal model
for toxicology studies was undertaken. Results from these studies
have
demonstrated a very similar expression pattern between hum
'"/>Page: 1 2 3 4 Related medicine technology :1.
The Past, Present and Future of HLA Typing2.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis3.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis4.
Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting5.
Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society6.
Generex Biotechnology to Make Presentations At 46th Annual Meeting
of the European Society of Pediatric Endocrinology7.
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference8.
ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference9.
Accelrys to Present to Investors at C.E. Unterberg Emerging Growth
Opportunities Conference10.
Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth
Conference and Attend Pacific Growth Equities Conference11.
Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference